The present invention relates to a metal phase transformation compound and a method for preparing the same.

The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.

The invention relates to a soft chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the soft chewable dosage form and wherein the soft chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the soft chewable dosage form.

Provided is a laxative tablet which includes magnesium oxide as a main constituent, wherein (1) the particle size by volume of 50% (D50) of particles which emerge when the tablet is suspended in water is 70 μm or less as determined by laser diffractometry, (2) the particle size by volume of 90% (D90) of the particles which emerge when the tablet is suspended in water is 130 μm or less as determined by laser diffractometry, and (3) the dissolution time of the tablet when the tablet is suspended in water according to the Japanese Pharmacopoeia—general testing methods—dissolution testing methods is 10 seconds or less.

Provided is a laxative tablet which includes magnesium oxide as a main constituent, wherein (1) the particle size by volume of 50% (D50) of particles which emerge when the tablet is suspended in water is 70 μm or less as determined by laser diffractometry, (2) the particle size by volume of 90% (D90) of the particles which emerge when the tablet is suspended in water is 130 μm or less as determined by laser diffractometry, and (3) the dissolution time of the tablet when the tablet is suspended in water according to the Japanese Pharmacopoeia—general testing methods—dissolution testing methods is 10 seconds or less.

Embodiments of a composition and/or combination comprising an anionic dietary supplement and 25-hydroxy vitamin D are disclosed. The anionic dietary supplement may be a negative dietary cation anion difference (DCAD) supplement and/or may comprise magnesium chloride, magnesium sulfate, ammonium chloride, ammonium sulfate, and calcium sulfate, and/or complexes thereof. Also disclosed are embodiments of a method for administrating the combination and/or composition to an animal, such as a ruminant. In certain embodiments, the animal is a dairy cow, and the method may be a method for increasing milk yield, and/or improving the health of the animal.

Embodiments of a composition and/or combination comprising an anionic dietary supplement and 25-hydroxy vitamin D are disclosed. The anionic dietary supplement may be a negative dietary cation anion difference (DCAD) supplement and/or may comprise magnesium chloride, magnesium sulfate, ammonium chloride, ammonium sulfate, and calcium sulfate, and/or complexes thereof. Also disclosed are embodiments of a method for administrating the combination and/or composition to an animal, such as a ruminant. In certain embodiments, the animal is a dairy cow, and the method may be a method for increasing milk yield, and/or improving the health of the animal.

A bioactive borate glass composition including, for example: 30 to 60% B.sub.2O.sub.3; 0.5 to 20% ZrO.sub.2; 3 to 30% Na.sub.2O; 0.1 to 15% K.sub.2O; 0.1 to 15% MgO; 5 to 30% CaO; and 1 to 5% P.sub.2O.sub.5 in mole percents based on 100 mol % of the total composition. Also disclosed is a method of making and method of using the compositions and the bioactive borate glass dentin treatment formulations.

A bioactive borate glass composition including, for example: 30 to 60% B.sub.2O.sub.3; 0.5 to 20% ZrO.sub.2; 3 to 30% Na.sub.2O; 0.1 to 15% K.sub.2O; 0.1 to 15% MgO; 5 to 30% CaO; and 1 to 5% P.sub.2O.sub.5 in mole percents based on 100 mol % of the total composition. Also disclosed is a method of making and method of using the compositions and the bioactive borate glass dentin treatment formulations.

A bioactive borate glass composition including, for example: 30 to 60% B.sub.2O.sub.3; 0.5 to 20% ZrO.sub.2; 3 to 30% Na.sub.2O; 0.1 to 15% K.sub.2O; 0.1 to 15% MgO; 5 to 30% CaO; and 1 to 5% P.sub.2O.sub.5 in mole percents based on 100 mol % of the total composition. Also disclosed is a method of making and method of using the compositions and the bioactive borate glass dentin treatment formulations.